Assignee
MERRIMACK PHARMACEUTICALS INC
US·37 granted patents·81 pending applications·327 citations·filing 2002–2020
Top patents by PatentIndex Score
118 records- 0198US8992970B2Liposomes useful for drug deliveryMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted Mar 31, 2015·39 cites·14 claims
- 0298US8703181B2Liposomes useful for drug deliveryMERRIMACK PHARMACEUTICALS INC·Filed 2012·Granted Apr 22, 2014·40 cites·17 claims
- 0398US7846440B2Antibodies against ErbB3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2008·Granted Dec 7, 2010·92 cites·18 claims
- 0497US10087464B2Compositions and methods for delivering nucleic acid to a cellMERRIMACK PHARMACEUTICALS INC·Filed 2016·Granted Oct 2, 2018·16 cites·6 claims
- 0596US9492442B2Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Nov 15, 2016·19 cites·30 claims
- 0695US9339497B2Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted May 17, 2016·17 cites·27 claims
- 0794US9718892B2Method of treating myocardial infarction by administering a bi-specific fusion proteinMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Aug 1, 2017·12 cites·10 claims
- 0894US9364473B2Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Jun 14, 2016·12 cites·29 claims
- 0992US9511155B2Compositions and methods for non-invasive imagingMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Dec 6, 2016·10 cites·19 claims
- 1092US9452162B2Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Sep 27, 2016·12 cites·35 claims
- 1191US10570119B2Inhibiting ataxia telangiectasia and Rad3-related protein (ATR)MERRIMACK PHARMACEUTICALS INC·Filed 2017·Granted Feb 25, 2020·4 cites·15 claims
- 1291US9982060B2Bi-specific fusion proteinsMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted May 29, 2018·9 cites·15 claims
- 1389US9226964B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted Jan 5, 2016·9 cites·37 claims
- 1485US9487588B2Antibodies against the ectodomain of ERBB3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted Nov 8, 2016·4 cites·4 claims
- 1584US9688761B2Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapiesMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Jun 27, 2017·4 cites·24 claims
- 1682US9458245B2ANTI-C-MET tandem Fc bispecific antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted Oct 4, 2016·6 cites·3 claims
- 1782US9345766B2Combination therapies comprising anti-ERBB3 agentsMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted May 24, 2016·2 cites·5 claims
- 1881US9518130B2Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancersMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted Dec 13, 2016·4 cites·22 claims
- 1979US9556274B2Monospecific and bispecific anti-IGF-1R and anti-ERBB3 antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Jan 31, 2017·2 cites·10 claims
- 2077US6730492B2Cell-based screening methodsMERRIMACK PHARMACEUTICALS INC·Filed 2002·Granted May 4, 2004·4 cites·4 claims
- 2174US10273304B2Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapiesMERRIMACK PHARMACEUTICALS INC·Filed 2017·Granted Apr 30, 2019·1 cites·36 claims
- 2273US9527914B2Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Dec 27, 2016·1 cites·6 claims
- 2372US9657108B2Dosage and administration of anti-EGFR therapeuticsMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted May 23, 2017·1 cites·6 claims
- 2470US9226966B2Dosage and administration for preventing cardiotoxicity in treatment with ERBB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Jan 5, 2016·2 cites·10 claims
- 2570US7423024B2Recombinant human alpha-fetoprotein as an immunosuppressive agentMERRIMACK PHARMACEUTICALS INC·Filed 2004·Granted Sep 9, 2008·1 cites·8 claims
- 2670US2009053254A1Recombinant human alpha-fetoprotein as an immunosuppressive agentMERRIMACK PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 2769US2010056761A1Antibodies against erbb3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 2869US2019292271A1Antibodies against the ectodomain of erbb3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2967US2014127136A1Liposomes useful for drug delivery to the brainMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3067US2016338956A1Liposomes Useful for Drug DeliveryMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3167US2014127238A1Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted responseMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3267US2016339014A1Liposomes Useful for Drug DeliveryMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3366US2017049768A1Methods for treating pancreatic cancer using combination therapiesMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3466US2016067182A1Methods and compositions for improving outcomes of liposomal chemotherapyMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3565US2016081928A1Liposomes Useful for Drug DeliveryMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3665US2014234314A1Antibodies against epidermal growth factor receptor (egfr) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3765US2016106672A1Liposomes Useful for Drug DeliveryMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3864US7083938B2Cell-based screening methodsMERRIMACK PHARMACEUTICALS INC·Filed 2004·Granted Aug 1, 2006·0 cites·5 claims
- 3964US2017065578A1Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4064US2017253662A1Dosage and administration of anti-egfr therapeuticsMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 4163US9920131B2Dosage and administration of anti-EGFR therapeuticsMERRIMACK PHARMACEUTICALS INC·Filed 2016·Granted Mar 20, 2018·0 cites·18 claims
- 4263US2017073427A1Antibodies against the ectodomain of erbb3 and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4362US2016228428A1Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4461US10072299B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Sep 11, 2018·0 cites·21 claims
- 4561US9938346B2Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2016·Granted Apr 10, 2018·0 cites·24 claims
- 4661US9902999B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Feb 27, 2018·0 cites·21 claims
- 4761US9885087B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Feb 6, 2018·0 cites·21 claims
- 4861US7208576B2Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2003·Granted Apr 24, 2007·4 cites·3 claims
- 4961US2014170668A1Monoclonal and oligoclonal anti-egfr antibodies for use in the treatment of tumors expressing predominantly high affinity egfr ligands or tumors expressing predominantly low affinity egfr ligandsMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 5060US9968694B2Compositions and methods for non-invasive imagingMERRIMACK PHARMACEUTICALS INC·Filed 2016·Granted May 15, 2018·0 cites·20 claims
Showing the top 50 of 118 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when MERRIMACK PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →